Prevenar (13v) Infant Drug Use Investigation
NCT02119104 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1087
Last updated 2017-06-19
Summary
The purpose of this study is to investigate post marketing use and safety of Prevnar ( 13v) in infants vaccinated for the first time at the age of 2 months, inclusive, to 7 months, exclusive.
Conditions
- Infants
Interventions
- DRUG
-
Prevenar (13v)
Prevenar (13v)
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Eligibility
- Min Age
- 2 Months
- Max Age
- 6 Months
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-03-31
- Primary Completion
- 2016-05-31
- Completion
- 2016-05-31
More Related Trials
-
Prevenar Special Use-result Surveillance in Japan (Regulatory PostMarketing Commitment Plan)
NCT01521897 ·Status: COMPLETED
-
Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13
NCT05408429 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants
NCT03550313 ·Status: TERMINATED ·Phase: PHASE2
-
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
NCT00384059 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Prevnar 13 on Ear Infections in Children
NCT01199016 ·Status: COMPLETED
-
Study Investigating Administration of Prevenar for Post-Marketing Surveillance
NCT00195390 ·Status: COMPLETED
-
Post Market Surveillance to Observe Safety of Prevenar13™ in Adults
NCT01834222 ·Status: COMPLETED
-
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
NCT00366678 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children
NCT00824655 ·Status: COMPLETED ·Phase: PHASE3
-
Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13®
NCT01392378 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Local Tolerability of Prevenar in Indian Children
NCT00488800 ·Status: COMPLETED
-
Impact of Prevnar 13 on Ear Infections in Children
NCT01272999 ·Status: COMPLETED
-
Postlicensure Observational Safety Study of 13vPnC Administered to Infants and Toddlers
NCT01128426 ·Status: COMPLETED
-
Study Evaluating Prevenar Immunogenicity in High Risk Children
NCT00581620 ·Status: COMPLETED ·Phase: PHASE4
-
20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants
NCT04379713 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.
NCT01193335 ·Status: COMPLETED ·Phase: PHASE4
-
Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.
NCT00227188 ·Status: COMPLETED
-
Study Evaluating Pneumococcal Vaccine in Healthy Infants
NCT00205803 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
NCT06824194 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)
NCT04031846 ·Status: COMPLETED ·Phase: PHASE3
-
Prevenar (PCV-7) Post-Licensure Safety Study In Russia
NCT01207583 ·Status: COMPLETED
-
Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine
NCT00373958 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.
NCT00366340 ·Status: COMPLETED ·Phase: PHASE3
-
Study Comparing Prevenar® to Pneumo 23 in Reducing Carriage in Children
NCT00580684 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants
NCT06524414 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2